Piper Jaffray
Piper Jaffray is a client-focused, middle market investment bank and institutional securities firm founded in 1895 and based in Minneapolis, Minnesota.
Its Investment Banking activities include raising capital through equity and debt financings for corporate clients; providing financial advisory services relating to mergers and acquisitions to consumer, financial institutions, health care, technology, alternative energy, business services, and industrial growth sectors; underwriting debt issuances for government and non-profit clients; and providing financial advisory and interest rate risk management services.
The company's equity and fixed income institutional sales and trading activities include equity and fixed income advisory and trade execution services for public and private corporations, public entities, non-profit clients, and institutional investors.
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Lowered to $111 at Piper Jaffray
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX): Reiterating Outperform Ahead of PDUFA in April - Piper Jaffray
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX): Full Steam Ahead For INGREZZA - Piper Jaffray
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX) Share Price Discounting Only Half of Its Pipeline - PiperJaffray
-
-
-
-
-
-
-
Notable Analyst Rating Changes 7/21: (GIS) (ANAC) (HHS) Upgraded; (TSLA) (EBAY) (CNC) Downgraded
-
-
-
-
-
-
-
Notable 52-Week Highs and 12/10: (UAL) (BLUE) (BMS) High; (OAS) (CVEO) (CONN) Low
-
-
-
-
-
-
-
Piper Jaffray Upgrades Neurocrine Biosciences (NBIX) to Overweight; Daisy PETAL Trial Hits on All Fronts
-
20,864 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

